21:19 , Nov 18, 2016 |  BC Week In Review  |  Company News

uniQure restructuring news

uniQure said it will reduce headcount by 50-60 (20-25%) to about 190 by YE17 to focus on key pipeline projects. The company expects the job cuts will save €5-€6 million ($5.4-$6.4 million) annually, while reprioritizing...
23:50 , Nov 15, 2016 |  BC Extra  |  Company News

uniQure paring down gene therapy portfolio

Gene therapy company uniQure N.V. (NASDAQ:QURE) said it will reduce headcount by 20-25%, eliminating 50-60 positions by YE17, in order to focus on key pipeline projects. The company expects the job cuts will save EUR 5-6...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Company News

uniQure N.V, Bristol-Myers deal

uniQure granted Bristol-Myers exclusive access to uniQure’s gene therapy technology platform for multiple disease targets. The deal includes AAV-S100A1, an adeno-associated virus (AAV) vector expressing S100 calcium binding protein A1 (S100A1). The compound...
00:22 , Apr 7, 2015 |  BC Extra  |  Top Story

BMS teams with uniQure for CV gene therapies

In less than a year, uniQure N.V. (NASDAQ:QURE) has parlayed its EUR 3 million ($4 million) acquisition of InoCard GmbH into an expansive deal with Bristol-Myers Squibb Co. (NYSE:BMY). News of the deal sent uniQure's...
07:00 , Aug 18, 2014 |  BC Week In Review  |  Company News

InoCard, uniQure deal

uniQure acquired InoCard for EUR1.5 million ($2 million) in cash and EUR1.5 million in stock up front. InoCard shareholders will also be eligible to receive undisclosed milestones and royalties. InoCard’s gene therapy, InoCor (...
07:00 , Aug 18, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Celltrion Inc. (KOSDAQ:068270) gained W1,750 to W41,450 last week after submitting an application to FDA for Remsima infliximab, a biosimilar of autoimmune drug Remicade from Johnson & Johnson (NYSE:JNJ) and Merck & Co. Inc. (NYSE:MRK)....